RE:RE:RE:RE:RE:RE:RE:Photodynamic therapy combined with immunotherapy: Nov 15/23Good post Longholder99.
In terms of patient welfare, it's gratifying to compare Adstiladrin's performance with that of Ruvidar PDT
Of 103 CIS patients treated with Adstiladrin 24 of them still had a CR 15 months after their initial treatment.
If Ruvidar PDT maintains only the current 33% CRR at 15 months this will mean 33 CR patients at 15 months.
So for just the first 100 patients there will be 9 more cancer-free patients in the group lucky enough to be in the Ruvidar trial than the Adstiladrin trial.
And the 33 Ruvidar patients are much more likely to remain cancer free than the 24 Adstiladrin patients.
Longholder99 wrote: While we await these huge moves for a small company started by an Engineer with huge foresight. We can and should consider and imagine the relief felt by these first patients living with healthy cancer free bladders that were headed to biohazard disposals. Bless this company and its supporters. To those who badmouth and seek to drag it down. Shame.